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Summary Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in patients with
depression can be reduced by antidepressants, which are thought to improve endogenous
glucocorticoid-mediated negative feedback. A proportion of peripherally released glucocorti-
coids need to enter brain tissue, protected by the blood—brain barrier (BBB), in order to achieve
this negative feedback effect at the level of the central nervous systems (CNS). The multidrug
resistance transporter P-glycoprotein (P-gp) has been shown to actively transport glucocorticoid
hormones and has been implicated in the regulation of glucocorticoid access to the CNS. Using an
in situ brain/choroid plexus perfusion method, we tested the hypothesis that the antidepressant
desipramine increases glucocorticoid accumulation in the mouse brain by inhibiting P-gp,
following either chronic treatment (8 days, 20 mg/kg/day, IP) or acute administration (20 min
brain perfusion in the presence of either 0.9 mM or 10 mM desipramine). Contrary to our
hypothesis, chronic treatment with desipramine did not affect the accumulation of [3H]dexa-
methasone in any sample compared to saline-treated mice. Acute desipramine had limited and
variable effects on glucocorticoid accumulation in the CNS, with accumulation of [3H]dexameth-
asone increased in the cerebellum, accumulation of [3H]cortisol reduced in the frontal cortex,
hypothalamus, and cerebellum, and accumulation of [3H]corticosterone (the endogenous gluco-
corticoid in rodents) not affected. Overall, under the conditions tested, these results do not
support the hypothesis that treatment with desipramine can inhibit P-gp at the BBB and
subsequently increase the accumulation of glucocorticoids in the brain.
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A disruption of the hypothalamic-pituitary-adrenal (HPA)
axis, the hormonal system that regulates the body’s response
to stress, has been consistently found in a number of psy-
chiatric disorders (Pariante, 2009). Due to inputs from both
limbic circuits and the brain stem, the HPA axis can respond
to both psychological and physical stressors (Lightman,
2008). Stimulation by a stressor induces the paraventricular
nucleus of the hypothalamus (PVN) to release corticotropin-
releasing hormone (CRH), signaling the anterior pituitary to
release adrenocorticotropin hormone (ACTH), which in turn
signals the release of glucocorticoids from the adrenal cor-
tex, in the form of cortisol in humans and corticosterone in
rodents (Lightman, 2008). Glucocorticoids then bind to intra-
cellular nuclear receptors, the mineralocorticoid receptor
(MR) and the glucocorticoid receptor (GR), in a number of
target tissues (reviewed in Pariante and Miller, 2001).
Hyperactivity of the HPA axis has been found in a large
percentage of patients with depression and, though the exact
site of the disruption in HPA axis regulation in patients with
depression is unknown, a key implicated factor is the gluco-
corticoid-mediated negative feedback by which endogenous
glucocorticoids control HPA axis activity (Pariante and Light-
man, 2008). Increased concentrations of plasma and cere-
brospinal fluid (CSF) cortisol, non-suppression of cortisol
secretion following administration of the synthetic glucocor-
ticoid dexamethasone (in the dexamethasone suppression or
the dexamethasone/CRH test), and increased volumes of the
pituitary and adrenal glands (Pariante, 2009), all suggest that
cortisol is hypersecreted and that negative feedback on the
HPA axis is reduced. Additionally, it has been shown that
normalization of these HPA abnormalities is necessary before
any resolution of clinical symptoms (Holsboer et al., 1982);
indeed, recent studies suggested that HPA hyperactivity may
be an indicator of a biological vulnerability to depression, as
shown by persistency of HPA axis abnormalities in both
acutely ill and recovered depressed patients (Vreeburg
et al., 2009; Juruena et al., 2010). Much work has examined
the role of GR in this HPA hyperactivity and the impaired
glucocorticoid-mediated negative feedback, as the GR seems
to be more important when endogenous hormones are high,
and has found that GR function in patients with depression is
impaired (Pariante, 2009). Interestingly, antidepressants
have been shown to exert direct effects on the GR (and on
the MR), including increasing receptor expression and func-
tion, which are likely to improve negative feedback on the
HPA axis and thus decreasing basal and stress-induced glu-
cocorticoid secretion in rodents and humans (Pariante,
2009).
In order to mediate the negative feedback control on the
HPA axis, a proportion of these glucocorticoids must enter
brain tissue, which is protected by the blood—brain barrier
(BBB), found at the level of the cerebral capillary endothelial
cells. In addition to the BBB, the free movement of molecules
from the blood is also restricted by the blood—cerebrospinal
fluid (CSF) barrier (BCSFB) which is found at the fluid-secret-
ing epithelium of the choroid plexus and at the arachnoid
membrane (Gazzin et al., 2008; Johanson et al., 2008).
Fenestrated capillaries that feed the choroid plexus allow
for relatively free movement of molecules into choroid
plexus tissue, with some of these molecules then beingtransported into CSF. The ventricular distribution of CSF-
borne signals occurs by bulk flow and there is no physical
restriction in the movement of molecules from the CSF to the
brain; however, movement from CSF to brain is limited
(Johanson et al., 2008). Nevertheless, passage through the
BCSFB may provide an ‘‘easier’’ route of access to the brain
compared with access through the restrictive BBB. Of special
note is the differential expression of transporters in capillary
endothelium (BBB) and choroidal epithelium (BCSFB) that
may contribute to differential access of the same molecules
to each barrier compartment (Gazzin et al., 2008). Addition-
ally, there are central nervous system (CNS) regions that have
non-barrier type capillaries; for example, fenestrated capil-
laries feed the posterior pituitary gland allowing free
exchange of blood-borne molecules between blood and tis-
sue. The posterior pituitary gland is an example of a circum-
ventricular organ (CVO), which are a group of self-contained
structures surrounded by physical restrictions, preventing
the free movement of molecules into non-CVO tissues (John-
son and Gross, 1993). Thus, as CNS tissues have a varied ease
of molecule penetration from the peripheral circulation, it is
necessary to evaluate the access to different tissues with
reference to the physiological penetration across the respec-
tive barriers.
The multidrug resistance transporter P-glycoprotein (P-
gp) has been characterized as a major contributor in the
phenomenon of highly lipophilic molecules penetrating the
brain from the blood at a much lower rate than expected, and
has been found to have numerous substrates, inhibitors and
modulators (Schinkel, 1999). In humans, MDR1 codes for the
major drug-transporting isoform of P-gp (Schinkel, 1999) and
the drug-transporting isoforms in rodents are mdr1a and
mdr1b, which together share 80% homology with the human
MDR1 (Borst and Schinkel, 1996). P-gp is expressed in a
number of tissues, including the liver, kidneys, intestine,
and adrenal cortex (Schinkel et al., 1997). Most importantly,
P-gp is expressed at the blood—CNS barriers; specifically, P-
gp has been identified in human and murine cerebral capillary
endothelial cells and found to actively transport substrates
from the basolateral (brain) side to the luminal (blood) side
of the cell (Cordon-Cardo et al., 1989; Schinkel, 1999). It has
also been detected in rat and rabbit choroid plexus (Choud-
huri et al., 2003; Kassem et al., 2007), as well as in isolated
choroid plexus lysates from wild-type FVB-abcb1a/b(+/+)
mice, but not those from the specific P-gp knockout mouse
strain, FVB-abcb1a/b(/) (Rao et al., 1999). Moreover, P-
gp has been shown to actively transport glucocorticoid hor-
mones and has been implicated in the regulation of gluco-
corticoid access to the CNS (Meijer et al., 1998; Karssen
et al., 2001; Uhr et al., 2002), although perhaps not to such a
large extent as originally hypothesized (Mason et al., 2008).
In 2004, in this Journal, we hypothesized that the activity
of P-gp at the BBB may be a target of antidepressant action
(Pariante et al., 2004). Specifically, we proposed that anti-
depressants can inhibit P-gp at the BBB, thus increasing the
access of glucocorticoids to the brain and improving the
glucocorticoid-mediated negative feedback. This hypothesis
was based on our in vitro data, showing that antidepressants
increased GR activity not only directly, by activating the
translocation of the GR from the cytoplasm to the nucleus,
but also indirectly, by increasing intracellular concentration
of glucocorticoids via inhibition of P-gp (Pariante et al., 1997,
Antidepressant effects on CNS glucocorticoids 13532001). Specifically, we found that intracellular levels of
[3H]cortisol, in mouse fibroblasts LMCAT cells and in primary
rat neuronal cultures, were increased by 24 h incubation of
cells with the P-gp inhibitor, verapamil, as well as by the
antidepressants, clomipramine and fluoxetine (Pariante
et al., 2003a,b); these effects were abolished when the
antidepressants and verapamil were incubated together
(Pariante et al., 2003a,b). Our later animal data also showed
that the effects of antidepressant treatment on GR expres-
sion and function were different in mice deficient for P-gp
(Yau et al., 2007). Specifically, 1 week of chronic desipramine
treatment increased GR mRNA transcription in the hippo-
campus and reduced plasma corticosterone concentrations of
FVB-abcb1a/b(+/+) mice, but not in FVB-abcb1a/b(/)
mice, which led us to conclude that P-gp is necessary for
desipramine to induce the effects on the GR expression and
HPA axis function in mice. However, until today we had not
yet tested whether antidepressant treatment could specifi-
cally increase glucocorticoid entry into the brains of mice by
inhibiting P-gp.
The aim of this current study is to test the hypothesis that
antidepressant treatment directly increases glucocorticoid
accumulation in the brain by a P-gp-mediated mechanism.
Our initial work in this area demonstrated that the accumu-
lation of [3H]dexamethasone is greater in the brains of FVB-
abcb1a/b(/) mice compared to FVB-abcb1a/b(+/+) mice
(Mason et al., 2008) and, in order to address our hypothesis,
we have now used our in situ brain/choroid plexus perfusion
in these mice to examine the effect of chronic treatment (8
days) with desipramine on the brain accumulation of [3H]dex-
amethasone. We have also conducted cross-competition stu-
dies to determine whether acute inhibition of P-gp by
desipramine (20 min) can increase the brain accumulation
of [3H]dexamethasone, as well as of the endogenous [3H]glu-
cocorticoids, cortisol and corticosterone.
2. Method
All procedures are within the guidelines of the Animals
(Scientific Procedures) Act, 1986, UK.
2.1. Animals
Adult FVB-abcb1a/b (+/+) and FVB-abcb1a/b(/) mice
were imported from Taconic Farms Inc. (Germantown, NY,
USA) and a breeding colony was established at King’s College
London under an academic breeding agreement. Genotype
was confirmed by PCR analysis (Harlan UK Ltd., Hillcrest,
Belton, Loughborough, UK) and it is recognized that Dr. Alfred
Schinkel of the Netherlands Cancer Institute is the creator of
the abcb1a/b-deficient mice. All animals were maintained
under standard conditions of temperature and lighting (lights
on at 0700 h and off at 1900 h) and given food and water ad
libitum.
2.2. Materials
2.2.1. Radiolabeled substances
[3H]cortisol (74.0 Ci/mmol), [3H]corticosterone (79.0 Ci/
mmol), [3H]dexamethasone (89.0 Ci/mmol) were purchased
from GE Healthcare (Buckinghamshire, UK). [14C]sucrose(0.49 Ci/mmol) was purchased from Moravek Biochemicals
(Brea, CA, USA).
2.2.2. Unlabeled substances
Desipramine hydrochloride was purchased from Sigma
(Poole, Dorset, UK). All materials were stored as recom-
mended by the suppliers.
2.3. Procedures
2.3.1. In situ brain/choroid plexus perfusion
technique
This technique has been described and validated previously
(Sanderson et al., 2007). Adult male mice (25—40 weeks and
25—46 g) were anaesthetized with a medetomidine hydro-
chloride (2 mg/kg, IP) and ketamine hydrochloride solution
(150 mg/kg, IP) and heparinized (100 Units, IP). The body
cavity was opened and the left ventricle cannulated with a
fine needle (25 gauge) connected to a perfusion circuit. A
Watson—Marlow peristaltic pump (323S/RL, Cornwall, UK)
was used to perfuse the heart in situ with a warmed (37 8C)
and oxygenated (95% O2; 5% CO2) artificial plasma (modified
Krebs-Henseleit mammalian Ringer solution) as detailed pre-
viously (Mason et al., 2008). With the start of perfusion
(5.0 ml/min), the right atrium was sectioned to create an
open circuit and allow drainage of the artificial plasma. In all
experiments, a 2.5 min pre-drug perfusion of artificial plasma
ensured removal of endogenous glucocorticoids from the
brain vasculature. [3H]dexamethasone (3.9 nM), [3H]cortisol
(3.6 nM) or [3H]corticosterone (3.8 nM) along with
[14C]sucrose (vascular or extracellular space marker; 0.5—
1.0 nM), was then administered by a slow-drive syringe pump
(model 22; Harvard Apparatus; Kent, UK) into the artificial
plasma. Following the desired isotope perfusion time period
up to 20 min, the mouse was decapitated. Selected areas of
the CNS, both HPA axis-related regions and major brain
regions (frontal cortex, hippocampus, hypothalamus, cere-
bellum, fourth ventricle choroid plexus, and pituitary gland,
consisting of both anterior and posterior sections), were
dissected and weighed. All these samples, together with
100 ml artificial plasma samples, were prepared for liquid
scintillation counting as described below.
2.3.2. Antidepressant treatment and corticosterone
measurement
Desipramine hydrochloride (dissolved in 0.9% saline at 1 mg/
ml) was injected (10 mg/kg, IP) twice daily for 8 days.
Injections were given between 0900—0930 h and 1600—
1630 h to coincide with the peak and trough of the natural
corticosterone fluctuation (Kotelevtsev et al., 1997). Before
the perfusion, animals were subjected to blood sampling
from the saphenous leg vein, and then deeply anesthetized
for the 5 min in situ brain/choroid plexus perfusion, as
detailed above. Blood samples were centrifuged at
13,793  g for 5 min at 20 8C and the resulting plasma sample
was snap frozen on dry ice. The plasma samples were trans-
ported to Dr. J.L.W. Yau (University of Edinburgh) and were
there analyzed for the concentration of corticosterone pre-
sent, as described in Yau et al. (2007).
It is of note that this study design is different from that in
our previous paper by Yau et al. (2007), in which all animals
were killed by decapitation, in the morning, 16 h after the
1354 B.L. Mason et al.last injection. The perfusion procedure must be conducted
immediately after anesthetizing of the animals; hence the
sacrificing of the mice was staggered throughout the day
(0900—1600 h). All mice were perfused the day following the
last desipramine injection, and thus were subjected to the
brain/choroid plexus perfusion 17—24 h after last injection.
2.3.3. Cross-competition studies
In separate sets of single-time point experiments, the
uptake of [3H]dexamethasone (3.9 nM), [3H]cortisol
(3.6 nM), or [3H]corticosterone (3.8 nM) was determined
in the presence of unlabeled desipramine (0.9 mM and10 mM,
dissolved in the artificial plasma) and compared to perfu-
sions in which no unlabeled desipramine was present. 0.9 mM
corresponds to the upper limit of the therapeutic plasma
concentration in patients taking desipramine (Yau et al.,
2007) and 10 mM has previously been shown to induce GR
translocation to the nucleus in vitro (Pariante et al., 1997).
All perfusions (including wild-type FVB-abcb1a/b(+/+) con-
trols, i.e., no desipramine present in the artificial plasma)
were 20 min in length, in order to allow sufficient time for
the desipramine to inhibit all potential transporters; desi-
pramine was present in the artificial plasma solution from
the beginning of the perfusion time. In all perfusion experi-
ments, [14C]sucrose (0.5—1.0 nM) was present as a vascular
or extracellular space marker.
2.3.4. Liquid scintillation counting
All samples were solubilized over at least 48 h in 0.5 ml of
Solvable (PerkinElmer Life and Analytical Sciences, Boston,
MA, USA). All samples were then vortexed, 3.5 ml of scin-
tillation counting fluid (Lumasafe; PerkinElmer Life andFigure 1 RCorrTissue% (ml 100 g
1) of [3H]dexamethasone in the brain
cerebellum, 1d) following 5 min perfusion in saline-treated and 
(abcb1a/b(+/+) mice: n = 12; abcb1a/b(/) mice: n = 11). * D
(P < 0.05, Two-Way ANOVAs, vascular space-corrected).Analytical Sciences) was then added and the samples vor-
texed again. The samples were then placed in a Packard
TriCarb 2100 or 2900TR (PerkinElmer, Beaconsfield, UK)
liquid scintillation counter for estimation of [3H] and [14C]
radioactivities. All results were corrected for background
radioactivity.
2.3.5. Expression of results
Data from all experiments are presented as mean  standard
error of the mean. The concentration of [3H] or [14C] radio-
activity in the brain tissue (dpm g1) is expressed as a
percentage of that in artificial plasma (dpm ml1) and is
referred to as RTissue %. In order to account for any differences
in vascular space, in reference to brain regions protected by
the BBB, or extracellular space, in reference to CNS samples
that are not protected by the BBB, the RTissue% values of the
radioactive glucocorticoids were corrected with the RTissue
values of [14C]sucrose, and termed RCorrTissue% and are
referred to as ‘‘vascular space-‘‘, or ‘‘extracellular space-
corrected’’, respectively, and are used when comparing
glucocorticoid values between strains.
2.3.6. Data analysis
The data from all the experiments are presented as mean
 standard error of the mean. The GraphPad statistical
program (GraphPad Prism, 5.0b Mac Version) was used for
all determinations. The level of significance was set at
(P < 0.05). Two-Way ANOVAs were used to compare uptake
of [3H]dexamethasone between treatment groups for each
individual region following chronic desipramine treatment;
Student’s t-tests were used to compare plasma corticoster-
one concentrations between groups; One-Way ANOVAs, fol- regions (frontal cortex, 1a; hippocampus, 1b; hypothalamus, 1c;
desipramine-treated abcb1a/b(+/+) and abcb1a/b(/) mice
enotes significance compared with FVB-abcb1a/b(+/+) mice
Figure 2 RCorrTissue% (ml 100 g
1) of [3H]dexamethasone in the choroid plexus (2a) and pituitary gland (2b) following 5 min perfusion
in saline-treated and desipramine-treated abcb1a/b(+/+) and abcb1a/b(/) mice (abcb1a/b(+/+) mice: n = 12; abcb1a/b(/)
mice: n = 11).
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uptake of [3H]dexamethasone, [3H]cortisol, or [3H]corticos-
terone between groups for each individual region in the
cross-competition studies.
3. Results
3.1. [3H]dexamethasone perfusion following
chronic desipramine treatment
3.1.1. Brain regions
The vascular space-corrected [3H]dexamethasone values are
presented in Fig. 1. The accumulation of [3H]dexamethasone
was significantly greater in the frontal cortex, hippocampus,
hypothalamus, and cerebellum of FVB-abcb1a/b(/) mice
compared to FVB-abcb1a/b(+/+) mice (P < 0.0001,
P = 0.018, P = 0.034, P < 0.0001, respectively, Two-Way ANO-
VAs, vascular space-corrected). Chronic treatment with desi-
pramine did not significantly affect the accumulation of
[3H]dexamethasone in any brain region studied when com-
pared to saline-treated controls, nor were there any inter-
actions between factors (P > 0.05, Two-Way ANOVAs,
vascular space-corrected).
3.1.2. Choroid plexus and pituitary gland
The extracellular space-corrected [3H]dexamethasone
values are presented in Fig. 2. The accumulation of [3H]dex-Figure 3 Plasma corticosterone (mg/dL) levels in saline-trea-
ted or desipramine-treated abcb1a/b(+/+) and abcb1a/b(/)
mice (abcb1a/b(+/+) mice: n = 10; abcb1a/b(/) mice: n = 8).
Desipramine was injected (10 mg/kg, IP) twice daily for 8 days.amethasone was not significantly different between strains
and chronic treatment with desipramine did not significantly
affect the uptake of [3H]dexamethasone in either the choroid
plexus or in the pituitary gland (P > 0.05, Two-Way ANOVAs,
corrected for extracellular space).
3.1.3. Plasma corticosterone
There was no statistically significant difference in the con-
centration of plasma corticosterone (mg/dL) following
chronic treatment with desipramine when all samples were
analyzed together (P > 0.05, Student’s t-tests, Fig. 3). How-
ever, it is important to emphasize that mice were sacrificed
at different times of the day and at varying intervals after the
last injection (i.e., 17—24 h; see Section 2). Of note, when
we analyzed the corticosterone concentrations only in those
animals sacrificed in the morning (n = 9; 17—20 h after the
last injection), corticosterone concentrations were lower
following desipramine (by 20%) but this did not attain sta-
tistical significance (P = 0.7, Student’s t-test, data not
shown).
3.2. [3H]glucocorticoid accumulation with acute
desipramine exposure
In order to further investigate the effect of desipramine
treatment on the CNS accumulation of [3H]glucocorticoids,
we have conducted acute studies using only a 20 min desi-
pramine exposure period In FVB-abcb1a/b(+/+) mice (i.e.,
wild-type controls). This allowed us to investigate the inter-
action of desipramine with any possible transporters.
3.2.1. Brain regions
The vascular space-corrected [3H]glucocorticoid values are
presented in Fig. 4. The accumulation of [3H]dexamethasone
in the cerebellum was significantly increased in the presence
of both concentrations of unlabeled desipramine (P = 0.0052,
One-Way ANOVA, vascular-space corrected, P < 0.01 for
0.9 mM and P < 0.05 for 10 mM, Tukey’s HSD) compared to
wild-type control mice. There were no changes in [3H]dex-
amethasone accumulation observed in the frontal cortex,
hippocampus or hypothalamus in the presence of either
concentration of desipramine.
The accumulation of [3H]cortisol in the frontal cortex,
hypothalamus, and cerebellum was significantly decreased in
Figure 4 RCorrTissue% (ml 100 g
1) of [3H]dexamethasone (4a), [3H]cortisol (4b), or [3H]corticosterone (4c) in the brain regions
following 20 min perfusion in the absence and presence 0.9 and 10 mM) of unlabeled desipramine in mice (n = 12 for [3H]dexametha-
sone; n = 14-19 for [3H]cortisol; n = 17—28 for [3H]corticosterone) * Denotes significance compared with wild-type control mice
(P < 0.05, Tukey’s HSD, following One-Way ANOVA).
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wild-type control mice (P = 0.0425, P = 0.0205, P = 0.0004,
respectively, Tukey’s HSD following One-Way ANOVAs, vascu-
lar-space corrected). There was also a decrease in the
accumulation of [3H]cortisol in the hippocampus when
10 mM was present; however, this did not attain statistical
significance (P = 0.07, Tukey’s HSD following One-Way
ANOVA, vascular space-corrected). No effect on [3H]cortisol
accumulation was not observed in the presence of 0.9 mM of
desipramine.
The accumulation of [3H]corticosterone was not signifi-
cantly different in any brain regions, in the presence of either
concentration of unlabeled desipramine (P > 0.05, One-Way
ANOVAs, vascular space-corrected).
3.2.2. Choroid plexus and pituitary gland
The extracellular space-corrected [3H]glucocorticoid
values are presented in Fig. 5. The accumulation of
[3H]dexamethasone in the choroid plexus and in the pitui-
tary gland was significantly increased in the presence of
0.9 mM of unlabeled desipramine compared to wild-type
controls (P < 0.05, P < 0.01, respectively, Tukey’s HSD
following One-Way ANOVAs, corrected for extracellular
space). There was no effect of the 10 mM concentration
of desipramine on [3H]dexamethasone accumulation in the
choroid plexus or pituitary gland. The accumulations of
[3H]cortisol and of [3H]corticosterone were not signifi-
cantly different in the absence or presence of either
concentration of unlabeled desipramine in either the chor-
oid plexus or pituitary gland (P > 0.05, One-Way ANOVAs,
corrected for extracellular space).4. Discussion
These experiments were conducted in order to directly test
the hypothesis that antidepressant treatment in mice can
inhibit P-gp and subsequently increase the accumulation of
glucocorticoids in the brain (Pariante et al., 2004). In our
previously published multiple-time point perfusion experi-
ments in mice (Mason et al., 2008), the most robust and
consistent effects of the efflux of glucocorticoids by P-gp
were detected with [3H]dexamethasone, rather than [3H]cor-
tisol or [3H]corticosterone, thus the effect of chronic desi-
pramine treatment was examined using [3H]dexamethasone.
Consistent with our previously published data (Mason et al.,
2008), the accumulation of [3H]dexamethasone was signifi-
cantly greater in the brain regions (frontal cortex, hippo-
campus, hypothalamus, and cerebellum) of FVB-abcb1a/
b(/) mice compared with FVB-abcb1a/b(+/+) mice. Con-
trary to our hypothesis, treatment for 8 days with desipra-
mine did not significantly affect the accumulation of
[3H]dexamethasone in any sample compared to saline-trea-
ted mice.
As our chronic antidepressant treatment experiment did
not indicate that desipramine was able to modulate the
function of P-gp, we used cross-competition studies to test
if acute administration of desipramine was able to directly
inhibit P-gp and increase the CNS accumulation of [3H]dex-
amethasone, [3H]cortisol, or [3H]corticosterone. We chose a
longer perfusion time of 20 min for these experiments in
order to allow time for the desipramine in the artificial
plasma to fully inhibit any possible transport mechanisms.
We used both 0.9 mM, which corresponds to the upper limit of
Figure 5 RCorrTissue% (ml 100 g
1) of [3H]dexamethasone (5a), [3H]cortisol (5b), or [3H]corticosterone (5a) in the choroid plexus or
pituitary gland following 20 min perfusion in the presence of 0.9 mM or 10 mM unlabeled desipramine in FVB mice (n = 12 for
3H]dexamethasone; n = 19 for [3H]cortisol; n = 26 for [3H]corticosterone); * Denotes significance compared with wild-type control mice
(P < 0.05, Tukey’s HSD, following One-Way ANOVA).
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ing desipramine (Yau et al., 2007), and 10 mM, which has
previously been shown (for desipramine and other antide-
pressants) to increase GR function and intracellular concen-
tration of glucocorticoids in vitro (Pariante et al., 1997,
2001, 2003a,b). The cross-competition studies are designed
in such a way as to inhibit the major contributing transporters
and to indicate directionality, i.e., a decrease in [3H]gluco-
corticoid in the presence of an excess of unlabeled desipra-
mine indicates the inhibition of an influx transporter. We
found that acute desipramine had some effects on glucocor-
ticoid entry into the brain, but overall these effects sug-
gested only a variable and limited action of desipramine on P-
gp, which was not consistent across the glucocorticoids
tested. Interestingly, we found evidence of the saturable
transport of [3H]dexamethasone and of [3H]cortisol, but no
evidence of the saturable transport of [3H]corticosterone.
Specifically, the accumulation of [3H]dexamethasone in the
cerebellum was increased in the presence of both 0.9 mM
and10 mM of unlabeled desipramine, indicating the presence
of an efflux mechanism able to transport [3H]dexamethasone
which is inhibited by desipramine. As we previously identified
increased accumulation of [3H]dexamethasone in this region
in FVB-abcb1a/b(/) mice compared to FVB-abcb1a/b(+/
+) mice (Mason et al., 2008), the transporter identified in this
current study may indeed be P-gp. These results are consis-
tent with our in vitro data and with our original hypothesis,
although clearly this effect is not present in other brain areas
or indeed after chronic desipramine administration. The
accumulation of [3H]dexamethasone in the choroid plexus
and in the pituitary gland was also increased in the presence
of 0.9 mM of unlabeled desipramine, but this is unlikely to be
due to P-gp inhibition as this transporter is not present in thepituitary (Mason et al., 2008). In contrast to the data for
[3H]dexamethasone, the accumulation of [3H]cortisol in the
frontal cortex, hypothalamus, and cerebellum (and, not
significantly, in the hippocampus), was reduced in the pre-
sence of 10 mM of unlabeled desipramine, suggesting that
there may be an influx transporter present at the level of the
BBB which is sensitive to desipramine. It is possible that this is
the transporter oatp2, previously identified in the cerebel-
lum (Mason et al., 2010). Finally, and perhaps most impor-
tantly in this context, the accumulation of
[3H]corticosterone, the endogenous glucocorticoid in mice,
was not significantly different in the brain regions in the
presence of either concentration of unlabeled desipramine,
and thus, under the conditions tested, our findings do not
support the notion that antidepressants modulate the HPA
axis in these animals by direct interactions with transporters
at the BBB which transport glucocorticoids.
A concern with our current findings arises when comparing
these present data to our previous findings in mice using
virtually the same antidepressant regime of 20 mg/day of
desipramine for 7 days (Yau et al., 2007). In this previous
study, we found that desipramine decreases corticosterone
concentrations in both FVB/N controls and in FVB-abcb1a/
b(/) mice, whereas in the current study we have not
found an effect of chronic desipramine treatment on plasma
corticosterone concentrations. We did however have signifi-
cant study design differences; specifically, in our previous
paper, blood was collected when all animals were killed by
decapitation in the morning, 16 h after the last injection,
whereas in the current paper, blood was collected through
blood sampling from the saphenous leg vein just before the
anesthesia, and mice were sacrificed at different times of the
day and following different intervals ranging from 17 to 24 h
1358 B.L. Mason et al.after the last injection. Clearly, the conditions in the present
study, while being optimal for the brain perfusion experi-
ments, are far from ideal to detect an effect of desipramine
on corticosterone concentrations, since these could be influ-
enced both by circadian rhythms and by the direct effects of
variable concentrations of desipramine. Indeed, in the sub-
sample of mice sacrificed in the morning we did find a small
(albeit not significant) reduction of corticosterone levels by
desipramine. Therefore, we believe that our different
results, showing a lack of effect of desipramine on plasma
corticosterone concentrations, shall not be considered a lack
of replication of our previous findings but rather a conse-
quence of the differences in study design. An additional
limitation of the study is that we collected a small volume
of blood from live animals and thus were unable to obtain
enough plasma to analyze the desipramine concentration in
addition to the corticosterone concentration, nor we were
able to source extra brain tissue to analyze for glucocorticoid
receptor (GR) mRNA values to compare to our previous data
published in Yau et al. (2007), as all brain tissue was sub-
mitted to radioactivity counting.
Overall, under the conditions tested, these results do not
support our original hypothesis that chronic treatment with
antidepressants inhibits P-gp and subsequently increases the
accumulation of glucocorticoids in the brain. Of note, since
we initially proposed this hypothesis in 2003, support for this
null finding has been accumulating. For example, one study in
mice has shown that treatment with fluoxetine, amitripty-
line, and mirtazapine fail to change the expression of P-gp or
to disrupt the linear relationship between corticosterone
levels in the plasma and in the brain (Weber et al., 2006).
More importantly, two recent studies have evaluated brain P-
gp function in vivo using positron emission tomography (PET;
de Klerk et al., 2009, 2010). In studies in rats, de Klerk et al.
(2009) have found that antidepressant treatment increases,
rather than inhibits, P-gp function, and Clarke et al. (2009)
have shown that administration of the P-gp inhibitor vera-
pamil increases antidepressant concentrations in brain.
Moreover, and of particular relevance to our hypothesis,
the same authors have also found that P-gp activity is
increased, rather than inhibited, in patients with major
depression who are taking antidepressants (de Klerk et al.,
2009). Therefore, our data indicating that desipramine does
not increase [3H]dexamethasone in the brains of mice are
consistent with the most recent evidence, which further
supports us in refuting our original hypothesis.
However, it is important to interpret our present findings
also in the light of our previous work which led us to conduct
this study. In vitro, P-gp is clearly inhibited by several anti-
depressants, as we and others have demonstrated using well-
validated pharmacological assays to measure P-gp activity
(Pariante et al., 2003b; Weber et al., 2005). However, in
pharmacological assays, desipramine induces only 14% of
inhibition of P-gp activity at 10 mM, a concentration that is
close to the maximum concentration that can be achieved in
vivo (Weber et al., 2005). Other antidepressants also show
similar degrees of P-gp inhibition (Pariante et al., 2003b;
Weber et al., 2005); therefore, it is possible that this small
degree of inhibition, while able to increase intracellular
glucocorticoids in vitro, is not enough to obtain an effect
on glucocorticoid entry into the brain in vivo, as it certainly
does not compare to the P-gp deficiency present in FVB-abcb1a/b(/) mice. Moreover, in the original in vitro work
in LMCAT cells and primary neuronal cortex, P-gp was never
fully identified as the transporter in question, and it is known
that the inhibitor used, verapamil, can also inhibit the efflux
transporter BCRP (Matsson et al., 2009). Certainly, it is
intriguing that our previous study in mice has found that
virtually the same antidepressant regime used in the present
study induces GR upregulation in the brain of FVB/N controls
mice but not of FVB-abcb1a/b(/), thus supporting the
notion that P-gp is involved in the effects of antidepressants
on the HPA axis (Yau et al., 2007). These effects, however,
could be explained by changes occurring in the periphery
rather than at the BBB, since P-gp is present also in the liver,
kidneys, intestine, and adrenal cortex (Schinkel, 1999).
Taken together with the aforementioned studies by de Klerk
et al. (2009, 2010) in rats and humans, and our own recent
work finding no evidence of P-gp contribution to entry of
endogenous glucocorticoids to the brain in mice (Mason
et al., 2008), our present study demonstrates that desipra-
mine is unlikely to regulate glucocorticoid effects on the
brain via P-gp inhibition.
Finally, it is very important to stress in this context that a
direct pathway by which antidepressants activate GR trans-
location and increase GR function has been clearly demon-
strated, via activation of intracellular kinases and
phosphorylation of the GR (reviewed in Mason and Pariante,
2006; Carvalho and Pariante, 2008; Anacker et al., 2011a).
Of note is our recent paper showing that antidepressants
increase human hippocampal neurogenesis via a GR-depen-
dent mechanism that requires PKA-signaling and GR phos-
phorylation (Anacker et al., 2011b). Moreover,
antidepressants can regulate the HPA axis via different
mechanisms besides increasing GR binding to DNA. For
example, recent data have shown that, in man, glucocorti-
coids can have very rapid non-linear effects on feedback at
the level of the pituitary gland, which comes on within a few
minutes and would not need to be associated with any
change in intracellular glucocorticoid levels (Russell
et al., 2010). Indeed, and in keeping with this concept, it
is now clear that there is only episodic exposure of tissues to
endogenous cortisol, as most circulating cortisol and corti-
costerone are inactive due to binding by corticosterone
binding globulin (CBG), and thus tissue levels can only rise
sharply at the endogenous cortisol peak pulses when the
binding to CBG is saturated (Cameron et al., 2010). There-
fore, these negative findings do not detract from the overall
model that the HPA axis is a direct target of antidepressant
action. On the contrary, by clarifying mechanisms that are
unlikely to be relevant, these data move us forward in
exploring alternative molecular pathways by which antide-
pressants can alter these biological systems.
Role of funding source
This work was supported by a UK Medical Research Council
(MRC) Clinician Scientist Fellowship to C.M. Pariante (G108/
603), and was supported by the Wellcome Trust [080268],
granted to S.A. Thomas. Neither funding source had any
further role in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.
Antidepressant effects on CNS glucocorticoids 1359Conflict of interest statement
The authors have no conflict of interest to declare.
Acknowledgments
Thanks to Joyce Yau, University of Edinburgh, for measure-
ment of plasma corticosterone.
References
Anacker, C., Zunszain, P.A., Carvalho, L.A., Pariante, C.M., 2011a.
The glucocorticoid receptor: pivot of depression and of antide-
pressant treatment? Psychoneuroendocrinology 36, 415—425.
Anacker, C., Zunszain, P.A., Cattaneo, A., Carvalho, L.A., Garabe-
dian, M.J., Thuret, S., Price, J., Pariante, C.M., 2011b. Antide-
pressants increase human hippocampal neurogenesis by
activating the glucocorticoid receptor. Mol. Psychiatr., in press.
Borst, P., Schinkel, A.H., 1996. What have we learnt thus far from
mice with disrupted P-glycoprotein genes? Eur. J. Cancer 32A,
985—990.
Cameron, A., Henley, D., Carrell, R., Zhou, A., Clarke, A., Lightman,
S., 2010. Temperature-responsive release of cortisol from its
binding globulin: a protein thermocouple. J. Clin. Endocr. Metab.
95, 4689—4695.
Carvalho, L.A., Pariante, C.M., 2008. In vitro modulation of the
glucocorticoid receptor by antidepressants. Stress 11, 411—424.
Choudhuri, S., Cherrington, N.J., Li, N., Klaassen, C.D., 2003.
Constitutive expression of various xenobiotic and endobiotic
transporter mRNSs in the choroid plexus of rats. Drug Metab.
Dispos. 31, 1337—1345.
Clarke, G., O’Mahoney, S.M., Cryan, J.F., Dinan, T.G., 2009. Verapa-
mil in treatment resistant depression: a role for the P-glycopro-
tein transporter? Human Psychopharm. 24, 217—223.
Cordon-Cardo, C., O’Brien, J.P., Casals, D., Rittman-Grauer, L.,
Biedler, J.L., Melamed, M.R., Bertino, J.R., 1989. Multidrug-
resistance gene (P-glycoprotein) is expressed by endothelial
cells at the blood—brain barrier sites. Proc. Natl. Acad. Sci.
86, 695—698.
de Klerk, O.L., Willemsen, A.T., Roosink, M., Bartels, A.L., Harry
Hendrikse, N., Bosker, F.J., den Boer, J.A., 2009. Locally in-
creased P-glycoprotein function in major depression: a PET study
with [11C]verapamil as a probe for P-glycoprotein function in the
blood—brain barrier. Int. J. Neuropsychopharm. 12, 895—904.
de Klerk, O.L., Bosker, F.J., Willemsen, A.T., Van Waarde, A., Visser,
A.K., de Jager, T., Dagyte, G., den Boer, J.A., Dierckx, R.A.,
Meerlo, P., 2010. Chronic stress and antidepressant treatment
have opposite effects on P-glycoprotein at the blood—brain
barrier: an experimental PET study in rats. J. Psychopharmacol.
24, 1237—1242.
Gazzin, S., Strazielle, N., Schmitt, C., Fevre-Montange, M., Ostrow,
J.D., Tirbelli, C., Ghersi-Egea, J.-F., 2008. Differential expression
of the multidrug resistance-related proteins ABCb1 and ABCc1
between blood—brain interfaces. J. Comp. Neurol. 510, 497—507.
Holsboer, F., Liebl, R., Hofschuster, E., 1982. Repeated dexametha-
sone suppression test during depressive illness. J. Affect. Disord.
4, 93—101.
Johanson, C.E., Duncan III, J.A., Klinge, P.M., Brinker, T., Stopa, E.G.,
Silverberg, G.D., 2008. Multiplicity of cerebrospinal fluid func-
tions: new challenges in health and disease. Cerebrospinal Fluid
Res. 5, 10—41.
Johnson, A.K., Gross, P.M., 1993. Sensory circumventricular organs
and brain homeostatic pathways. FASEB J. 7, 678—686.
Juruena, M.F., Cleare, A.J., Papadopoulos, A.S., Poon, L., Lightman,
S., Pariante, C.M., 2010. The prednisolone suppression test indepression: dose—response and changes with antidepressant
treatment. Psychoneuroendocrinology 35, 1486—1491.
Karssen, A.M., Meijer, O.C., van der Sandt, I.C.J., Lucassen, P.J., de
Lange, E.C.M., de Boer, A.G., de Kloet, E.R., 2001. Multidrug
resistance p-glycoprotein hampers the access of cortisol but not
of corticosterone to mouse and human brain. Endocrinology 142,
2686—2694.
Kassem, N.A., Deane, R., Segal, M.B., Chen, R., Preston, J.E., 2007.
Thyroxine (T4) transfer from CSF to choroid plexus and ventricular
brain regions in rabbit: contributory role of P-glycoprotein and
organic anion transporting polypeptides. Brain Res. 1181, 44—50.
Kotelevtsev, Y., Holmes, M.C., Burchell, A., Houston, P.M., Schmoll,
D., Jamieson, P., Best, R., Brown, R., Edwards, C.R.W., Seckl,
J.R., Mullins, J.J., 1997. 11ß-hydroxysteroid dehydrogenase type
1 knockout mice show attenuated glucocorticoid-inducible
responses and resist hyperglycemia on obesity or stress. Proc.
Natl. Acad. Sci. 94, 14924—14929.
Lightman, S.L., 2008. The neuroendocrinology of stress: a never
ending story. J. Neuroendocrinol. 20, 880—884.
Matsson, P., Pedersen, J.M., Norinder, U., Bergstro¨m, C.A., Artursson,
P., 2009. Identification of novel specific and general inhibitors of the
three major human ATP-binding cassette transporters P-gp, BCRP
and MRP2 among registered drugs. Pharm. Res. 26, 1816—1831.
Mason, B.L., Pariante, C.M., 2006. The effects of antidepressants on
the hypothalamic-pituitary-adrenal axis. Drug News Perspect. 19,
603—608.
Mason, B.L., Pariante, C.M., Thomas, S.A., 2008. A revised role for P-
glycoprotein in the brain distribution of dexamethasone, cortisol,
and corticosterone in wild-type and ABCB1A/B-deficient mice.
Endocrinology 149, 5244—5253.
Mason, B.L., Pariante, C.M., Jamel, S., Thomas, S.A., 2010. Central
nervous system (CNS) delivery of glucocorticoids is fine-tuned by
saturable transporters at the blood—CNS barriers. Endocrinology
151, 5294—5305.
Meijer, O.C., de Lange, E.C.M., Breimer, D.D., de Boer, A.G., Workel,
J.O., de Kloet, E.R., 1998. Penetration of dexamethasone into
brain glucocorticoid targets is enhanced in mdr1a p-glycoprotein
knockout mice. Endocrinology 139, 1789—1793.
Pariante, C.M., Pearce, B.D., Pisell, T.L., Owens, M.J., Miller, A.H.,
1997. Steroid-independent translocation of the glucocorticoid
receptor by the antidepressant desipramine. Mol. Pharmacol.
52, 571—581.
Pariante, C.M., Makoff, A., Lovestone, S., Feroli, S., Heyden, A.,
Miller, A.H., et al., 2001. Antidepressants enhance glucocorticoid
receptor function in vitro by modulating the membrane steroid
transporters. Br. J. Pharmacol. 134, 1335—1343.
Pariante, C.M., Miller, A.H., 2001. Glucocorticoid receptors in major
depression: relevance to pathophysiology and treatment. Biol.
Psychiatr. 49, 391—404.
Pariante, C.M., Hye, A., Williamson, R., Makoff, A., Lovestone, S.,
Kerwin, R.W., 2003a. The antidepressant clomipramine regulates
cortisol intracellular concentrations and glucocorticoid receptor
expression in fibroblasts and rat primary neurones. Neuropsycho-
pharmacology 28, 1553—1561.
Pariante, C.M., Kim, R.B., Makoff, A., Kerwin, R.W., 2003b. Antide-
pressant fluoxetine enhances glucocorticoid receptor function in
vitro by modulating membrane steroid transporters. Br. J. Phar-
macol. 139, 1111—1118.
Pariante, C.M., Thomas, S.A., Lovestone, S., Makoff, A., Kerwin,
R.W., 2004. Do antidepressants regulate how cortisol affects the
brain? Psychoneuroendocrinology 29, 423—447.
Pariante, C.M., 2009. Risk factors for development of depression and
psychosis: glucocorticoid receptors and pituitary implications for
treatment with antidepressants and glucocorticoids. Ann. N. Y.
Acad. Sci. 1179, 144—152.
Pariante, C.M., Lightman, S.L., 2008. The HPA axis in major depres-
sion: classical theories and new developments. Trends Neurosci.
31, 464—468.
1360 B.L. Mason et al.Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., Snyder, A.Z., Finch, R.A.,
Sartorelli, A.C., Piwnica-Worms, D., 1999. Choroid plexus epithe-
lial expression of MDR1 P-glycoprotein and multidrug resistance-
associated protein contribute to the blood—cerebrospinal-fluid
drug-permeability barrier. Proc. Natl. Acad. Sci. 96, 3900—3905.
Russell, G.M., Henley, D.E., Leendertz, J., Douthwaite, J.A., Wood,
S.A., Stevens, A., Woltersdorff, W.W., Peeters, B.W., Ruigt, G.S.,
White, A., Veldhuis, J.D., Lightman, S.L., 2010. Rapid glucocor-
ticoid inhibition of hypothalamic-pituitary-adrenal ultradian ac-
tivity in healthy males. J. Neurosci. 30, 6106—6115.
Sanderson, L., Khan, A., Thomas, S., 2007. Distribution of suramin, an
antitrypanasomal drug, across the blood—brain and blood—cere-
brospinal fluid interfaces in wild-type and P-glycoprotein transport-
er-deficient mice. Antimicrob. Agents Chemother. 51, 3136—3146.
Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A.A.M., van Deemter,
L., Smit, J.J.M., van der Valk, M.A., Woordouw, A.C., Spits, H.,
van Tellingen, O., Zulmans, J.M.J.M., Fibe, W.E., Borst, P., 1997.
Normal viability and altered pharmacokinetics in mice lacking
mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad.
Sci. 94, 4028—4033.
Schinkel, A.H., 1999. P-glycoprotein, a gatekeeper in the blood—
brain barrier. Adv. Drug Deliv. Rev. 36, 179—194.Uhr, M., Holsboer, F., Muller, M.B., 2002. Penetration of endogenous
steroid hormones corticosterone, cortisol, aldosterone and pro-
gesterone into the brain is enhanced in mice deficient for both
mdr1a and mdr1b p-glycoproteins. J. Neuroendcrinol. 14,
753—759.
Vreeburg, S.A., Hoogendijk, W.J.G., van Pelt, J., DeRijk, R.H.,
Verhagen, J.C.M., van Dyck, R., Smit, J.H., Zitman, F.G., Pen-
ninx, B.W.J.H., 2009. Major depressive disorder and hypothalam-
ic-pituitary-adrenal axis activity: results from a large cohort
study. Arch. Gen. Psychiatr. 66, 617—626.
Weber, C.-C., Eckert, G.P., Mu¨ller, W.E., 2006. Effects of antidepres-
sants on the brain/plasma distribution of corticosterone. Neu-
ropsychopharmacology 31, 2443—2448.
Weber, C.-C., Kressmann, S., Ott, M., Fricker, G., Mu¨ller, W.E., 2005.
Inhibition of P-glycoprotein function by several antidepressants
may not contribute to clinical efficacy. Pharmacopsychiatry 38,
293—300.
Yau, J.L.W., Noble, J., Thomas, S., Kerwin, R., Morgan, P.E., Light-
man, S., Seckl, J.R., Pariante, C.M., 2007. The antidepressant
desipramine requires the ABCB1 (mdr1)-type p-glycoprotein to
upregulate the glucocorticoid receptor in mice. Neuropsycho-
pharmacology 32, 2520—2529.
